Growth hormone may cut IV feeding needs for short bowel patients
NCT ID NCT07691125
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial tests whether injections of recombinant human growth hormone can reduce the amount of intravenous (IV) nutrition needed by adults with short bowel syndrome. About 100 participants who rely on IV nutrition will receive the hormone for 4 weeks, and researchers will measure changes in their IV support volume. The goal is to see if this treatment can ease the burden of daily IV feeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant human growth hormone injection
- What this could lead to
- If it works, this could reduce the amount of IV nutrition needed, making daily life easier for people with short bowel syndrome.
- What could go wrong
- This is a small, early-phase trial without a placebo group, so results may not be definitive. Growth hormone can have side effects like joint pain or fluid retention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME (SBS) IN ADULTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Eastern Theater Command
RECRUITINGNanjing, Jiangsu, 210002, China
-
Zhongshan Hospital Affiliated to Xiamen University
RECRUITINGXiamen, Fujian, 361004, China